Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Benitec and Biomics Join to Develop RNAi Drug for Hepatitis B

publication date: Sep 10, 2009

Benitec Limited and China-based Biomics Biotechnologies Co. have signed a binding agreement to collaborate on an RNA interference treatment for chronic hepatitis B virus (HBV) infection. Benitec, an Australian biotechnology company, will contribute its proprietary DNA-directed RNAi (ddRNAi) technology. Biomics of Nantong has developed a full-sites siRNA library, drug target screening and identification, siRNA structure modification and drug delivery systems. More details...

Stock Symbol: (ASX: BLT)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here